gabexate has been researched along with Pancreatitis, Chronic in 8 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Pancreatitis, Chronic: INFLAMMATION of the PANCREAS that is characterized by recurring or persistent ABDOMINAL PAIN with or without STEATORRHEA or DIABETES MELLITUS. It is characterized by the irregular destruction of the pancreatic parenchyma which may be focal, segmental, or diffuse.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aims of the study are to clarify the pathophysiological differences among early chronic pancreatitis (ECP), functional dyspepsia with pancreatic (FD-P) enzyme abnormalities and FD patients and to determine whether camostat mesilate, pancrelipase, and rabeprazole triple therapy improve FD symptoms in the ECP patients and FD-P patients in cross-over way." | 7.91 | Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. ( Agawa, S; Futagami, S; Gudis, K; Higuchi, K; Iwakiri, K; Kaneko, K; Kawamoto, C; Kodaka, Y; Murakami, M; Sakasegawa, N; Ueki, N; Wakabayashi, M; Yamawaki, H, 2019) |
| "The results of the present study suggest that camostat greatly inhibits pancreatic inflammation and prevents and reverses fibrosis and atrophy of the pancreas in the genetically obese and CCK-1 receptor-deficient OLETF rats." | 7.73 | Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats. ( Jia, D; Otsuki, M; Taguchi, M, 2005) |
| " Adverse events will be recorded." | 6.90 | A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC). ( Hart, PA; Nuttall, J; Ramsey, ML, 2019) |
| "The aims of the study are to clarify the pathophysiological differences among early chronic pancreatitis (ECP), functional dyspepsia with pancreatic (FD-P) enzyme abnormalities and FD patients and to determine whether camostat mesilate, pancrelipase, and rabeprazole triple therapy improve FD symptoms in the ECP patients and FD-P patients in cross-over way." | 3.91 | Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. ( Agawa, S; Futagami, S; Gudis, K; Higuchi, K; Iwakiri, K; Kaneko, K; Kawamoto, C; Kodaka, Y; Murakami, M; Sakasegawa, N; Ueki, N; Wakabayashi, M; Yamawaki, H, 2019) |
| "The results of the present study suggest that camostat greatly inhibits pancreatic inflammation and prevents and reverses fibrosis and atrophy of the pancreas in the genetically obese and CCK-1 receptor-deficient OLETF rats." | 3.73 | Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats. ( Jia, D; Otsuki, M; Taguchi, M, 2005) |
| "To investigate the effects of Guizhi Decoction, Chaihu Guizhi Decoction, Xiaochaihu Decoction and camostat on rat spontaneous chronic pancreatitis and the pathological relationships between formulas and syndromes." | 3.73 | [Effects of Chinese herbal medicines on spontaneous chronic pancreatitis in rats and the pathological relationships between formulas and syndromes]. ( Li, YQ; Motoo, Y; Shen, HY; Su, SB; Yoshiharu, M, 2006) |
| " Adverse events will be recorded." | 2.90 | A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC). ( Hart, PA; Nuttall, J; Ramsey, ML, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ramsey, ML | 1 |
| Nuttall, J | 1 |
| Hart, PA | 1 |
| Yamawaki, H | 1 |
| Futagami, S | 1 |
| Kaneko, K | 1 |
| Agawa, S | 1 |
| Higuchi, K | 1 |
| Murakami, M | 1 |
| Wakabayashi, M | 1 |
| Sakasegawa, N | 1 |
| Kodaka, Y | 1 |
| Ueki, N | 1 |
| Gudis, K | 1 |
| Kawamoto, C | 1 |
| Iwakiri, K | 1 |
| Daniluk, J | 1 |
| Liu, Y | 1 |
| Deng, D | 1 |
| Chu, J | 1 |
| Huang, H | 1 |
| Gaiser, S | 1 |
| Cruz-Monserrate, Z | 1 |
| Wang, H | 1 |
| Ji, B | 1 |
| Logsdon, CD | 1 |
| Jia, D | 1 |
| Taguchi, M | 1 |
| Otsuki, M | 3 |
| Su, SB | 1 |
| Li, YQ | 1 |
| Shen, HY | 1 |
| Motoo, Y | 2 |
| Yoshiharu, M | 1 |
| Ito, T | 1 |
| Itoi, T | 1 |
| Shimosegawa, T | 1 |
| Funakoshi, A | 1 |
| Shiratori, K | 1 |
| Naruse, S | 1 |
| Kuroda, Y | 1 |
| Nagashio, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1, Single Dose PK and Safety Study With NI-03 Followed by a Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of NI-03 When Compared to Placebo in Subjects With Chronic Pancreatitis[NCT02693093] | Phase 1/Phase 2 | 264 participants (Actual) | Interventional | 2016-02-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for gabexate and Pancreatitis, Chronic
| Article | Year |
|---|---|
Action of antiproteases on fibrosis in experimental chronic pancreatitis.
Topics: Animals; Disease Models, Animal; Esters; Fibrosis; Gabexate; Guanidines; Pancreatitis, Chronic; Prot | 2007 |
Antiproteases in the treatment of chronic pancreatitis.
Topics: Animals; Esters; Gabexate; Guanidines; Humans; Pancreatitis, Chronic; Trypsin Inhibitors | 2007 |
1 trial available for gabexate and Pancreatitis, Chronic
| Article | Year |
|---|---|
A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Clinical Trials, Phase I as Topic; C | 2019 |
5 other studies available for gabexate and Pancreatitis, Chronic
| Article | Year |
|---|---|
Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities.
Topics: Abdominal Pain; Aged; Benzamides; Drug Therapy, Combination; Dyspepsia; Esters; Female; Gabexate; Ga | 2019 |
An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Ceruletide; Cyclooxygenase 2 | 2012 |
Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats.
Topics: Actins; Amylases; Animals; Atrophy; Eating; Esters; Fibrosis; Gabexate; Guanidines; Interleukin-6; L | 2005 |
[Effects of Chinese herbal medicines on spontaneous chronic pancreatitis in rats and the pathological relationships between formulas and syndromes].
Topics: Animals; Antigens, Neoplasm; Biomarkers, Tumor; Drugs, Chinese Herbal; Esters; Gabexate; Guanidines; | 2006 |
Pancreatic diabetes in a follow-up survey of chronic pancreatitis in Japan.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus; Esters; Female; Follow-Up Studies; Gabexate; Guan | 2007 |